Body weight
weight loss
SECONDARY, INSULIN SENSITIVITY
PEG-Loxe treatment resulted in significant weight loss compared to metformin treatment during the trial period. After 16 weeks, the primary endpoints (least-square mean (LSM) weight loss) were 7.52 kg (8.37%) and 2.96 kg (3.00%) for the PEG-Loxe and metformin groups, respectively, with a between-group mean difference of 4.55 kg (95% CI: 3.43, 5.67; Efficacy endpoints during the 16-week treatment period: time course of absolute Primary and secondary endpoints at week 16.BMI, body mass index; WC, waist circumference; VFA, visceral fat area; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; HOMA2-%B, updated homeostatic model assessment for b-cell function; HOMA2-%S, updated homeostatic model assessment for insulin sensitivity; TC, total cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.After 16 weeks, the proportions of patients with a weight loss of ≥5% were 61.5% and 25.0% in the PEG-Loxe and metformin groups (